Jefferies Adjusts Price Target on Moderna to $215
Jefferies has lowered its price target for Moderna, Inc. from $230 to $215.
Stocks · News reference
Tempus AI expands its collaboration with Moderna and Merck to support sample collection and NGS services for intismeran autogene and Keytruda.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Jefferies has lowered its price target for Moderna, Inc. from $230 to $215.
The non-small cell lung cancer market is shifting toward precision, biomarker-guided treatment sequencing. ESMO 2026 presented Phase III data showing savolitinib plus osimertinib improved survival in MET-altered EGFR-mutated NSCLC, divarasib outperformed approved KRAS G12C inhibitors, and TROP2-directed ADCs demonstrated durable gains. The 7MM NSCLC market is projected to double from USD 33 billion in 2025 to USD 67 billion by 2036, driven by expanded screening, biomarker-driven therapies, and label expansions into earlier-stage disease.
The global pharmaceutical market is valued at USD 1.88 trillion in 2026 and is projected to reach USD 3.20 trillion by 2035 at a CAGR of 6.10%. Growth is concentrated in obesity and oncology therapies, with U.S. pricing deals and Section 232 tariffs reshaping manufacturing. North America holds 42% of the market, while companies with strong positions in GLP-1 medicines and cancer therapies are growing significantly faster than the market.
Bristol Myers Squibb has released the first clinical data from two Phase 3 studies in the ADEPT program evaluating KarXT for the treatment of psychosis associated with Alzheimer's disease.
Filed: 2026-11-18 AccNo: 0001193125-26-466240 Size: 212 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
Merck & Co., Inc. announced that Thomas H. Glocer will retire from its Board of Directors in May 2027 and that Douglas M. Baker, Jr. has been appointed as the new Independent Lead Director.